Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 46,385.0 | 42,518.0 | 26,145.0 | 22,561.0 | 20,776.0 | 19,427.0 | 16,560.0 | 15,879.0 |
| Revenue growth | 9.1% | 62.6% | 15.9% | 8.6% | 6.9% | 17.3% | 4.3% | -3.1% |
| Cost of goods sold | 19,963.0 | 21,461.0 | 9,213.0 | 6,564.0 | 6,111.0 | 4,969.0 | 3,909.0 | 3,932.0 |
| Gross profit | 26,422.0 | 21,057.0 | 16,932.0 | 15,997.0 | 14,665.0 | 14,458.0 | 12,651.0 | 11,947.0 |
| Gross margin | 57.0% | 49.5% | 64.8% | 70.9% | 70.6% | 74.4% | 76.4% | 75.2% |
| Selling, general and administrative | 7,690.0 | 7,661.0 | 4,871.0 | 4,551.0 | 4,751.0 | 4,979.0 | 4,841.0 | 4,822.0 |
| Research and development | 11,354.0 | 11,143.0 | 6,148.0 | 6,332.0 | 6,468.0 | 5,012.0 | 5,920.0 | 4,534.0 |
| EBITA | 17,578.0 | 715.0 | 7,213.0 | 5,312.0 | 7,006.0 | 7,541.0 | 2,447.0 | 2,854.0 |
| EBITA margin | 37.9% | 1.7% | 27.6% | 23.5% | 33.7% | 38.8% | 14.8% | 18.0% |
| Amortization of intangibles | 10,200.0 | 9,900.0 | 1,300.0 | 198.0 | 190.0 | 178.0 | 183.0 | 286.0 |
| EBIT | 7,378.0 | -9,185.0 | 5,913.0 | 5,114.0 | 6,816.0 | 7,363.0 | 2,264.0 | 2,568.0 |
| EBIT margin | 15.9% | -21.6% | 22.6% | 22.7% | 32.8% | 37.9% | 13.7% | 16.2% |
| Pre-tax income | 8,098.0 | -6,871.0 | 4,975.0 | 5,968.0 | 5,131.0 | 5,915.0 | 2,077.0 | 2,381.0 |
| Income taxes | 1,084.0 | 2,124.0 | 1,515.0 | 1,021.0 | 4,156.0 | 1,408.0 | 446.0 | 352.0 |
| Tax rate | 13.4% | | 30.5% | 17.1% | 81.0% | 23.8% | 21.5% | 14.8% |
| Net income | 6,994.0 | -9,015.0 | 3,439.0 | 4,920.0 | 1,007.0 | 4,457.0 | 1,565.0 | 2,004.0 |
| Net margin | 15.1% | -21.2% | 13.2% | 21.8% | 4.8% | 22.9% | 9.5% | 12.6% |
| |
| Diluted EPS | $3.12 | ($3.99) | $2.01 | $3.01 | $0.61 | $2.65 | $0.93 | $1.20 |
| Shares outstanding (diluted) | 2,245.0 | 2,258.0 | 1,712.0 | 1,637.0 | 1,652.0 | 1,680.0 | 1,679.0 | 1,670.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|